Answers are grounded in this paper and cite their sources.
This study demonstrates that targeting arf6 modifies lipid rafts, reducing inflammation in cell models, suggesting a new therapeutic path.
Partitioning of inflammatory receptors into lipid rafts is essential for their function, making lipid rafts a promising target for anti-inflammatory therapies. However, the practical application of lipid raft-targeted therapies has been limited by a lack of mechanistic understanding of their regulation. In this study, we demonstrate that targeting the Arf6-dependent recycling pathway effectively modifies lipid rafts and mitigates inflammation. Using Oxy210, a synthetic oxysterol, we observed significant anti-inflammatory effects both in vivo and in vitro. These effects were linked to an increased abundance of ABCA1, enhanced cholesterol efflux, and alterations in the abundance and composition of lipid rafts. Mechanistically, Oxy210 disrupted the recycling checkpoint in late endosomes by reducing the abundance and activation of the small GTPase Arf6 and decreasing PI(4,5)P2 levels. This impaired lipid raft recycling to the cell surface and simultaneously reduced ABCA1 internalization. These findings highlight a novel approach to modulating lipid raft-dependent pathological pathways, with potential applications in treating inflammation, neurodegeneration, and infectious diseases.
No takes yet. Share an insight, caveat, or question.
Mukhamedova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: